A Novel Small-molecule Tumor Necrosis Factor α Inhibitor Attenuates Inflammation in a Hepatitis Mouse Model*

Background: Most commercial TNFα inhibitors are biomacromolecules. Results: A lead compound named C87 was identified using computer-aided drug design and could attenuate murine acute hepatitis. Conclusion: C87 was one of the first effective small-molecule inhibitors of TNFα identified to date. Significance: The study highlights the effectiveness of combining virtual screening with functional assays for developing novel small-molecule TNFα inhibitors. Overexpression of tumor necrosis factor α (TNFα) is a hallmark of many inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and septic shock and hepatitis, making it a potential therapeutic target for clinical interventions. To explore chemical inhibitors against TNFα activity, we applied computer-aided drug design combined with in vitro and cell-based assays and identified a lead chemical compound, (E)-4-(2-(4-chloro-3-nitrophenyl) (named as C87 thereafter), which directly binds to TNFα, potently inhibits TNFα-induced cytotoxicity (IC50 = 8.73 μm) and effectively blocks TNFα-triggered signaling activities. Furthermore, by using a murine acute hepatitis model, we showed that C87 attenuates TNFα-induced inflammation, thereby markedly reducing injuries to the liver and improving animal survival. Thus, our results lead to a novel and highly specific small-molecule TNFα inhibitor, which can be potentially used to treat TNFα-mediated inflammatory diseases.

[1]  C. Trautwein,et al.  The role of TNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer. , 2012, European journal of cell biology.

[2]  B. Aggarwal,et al.  Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. , 2012, Blood.

[3]  D. Vinay,et al.  The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases , 2011, Clinical and experimental immunology.

[4]  Y. Yoshioka,et al.  Solution of the Structure of the TNF-TNFR2 Complex , 2010, Science Signaling.

[5]  Miriam Davis,et al.  TNF receptor 2 pathway: drug target for autoimmune diseases , 2010, Nature Reviews Drug Discovery.

[6]  Wim Declercq,et al.  Tumor necrosis factor-mediated cell death: to break or to burst, that’s the question , 2010, Cellular and Molecular Life Sciences.

[7]  P. Emery,et al.  Aspects of TNF inhibitor therapy in rheumatoid arthritis , 2010, Modern rheumatology.

[8]  S. Cuzzocrea,et al.  TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. , 2009, Current medicinal chemistry.

[9]  A. Rubbert-Roth,et al.  Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review , 2009, Arthritis research & therapy.

[10]  Xiaodong Wang,et al.  TNF-α Induces Two Distinct Caspase-8 Activation Pathways , 2008, Cell.

[11]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[12]  Akira Yamamoto,et al.  Creation and X-ray Structure Analysis of the Tumor Necrosis Factor Receptor-1-selective Mutant of a Tumor Necrosis Factor-α Antagonist* , 2008, Journal of Biological Chemistry.

[13]  J. Bradley,et al.  TNF‐mediated inflammatory disease , 2008, The Journal of pathology.

[14]  R. Baron,et al.  A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. , 2007, Arthritis and rheumatism.

[15]  C. Pham,et al.  The NF-κB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease , 2006, Cell Death and Differentiation.

[16]  M. Karin,et al.  The E3 Ubiquitin Ligase Itch Couples JNK Activation to TNFα-induced Cell Death by Inducing c-FLIPL Turnover , 2006, Cell.

[17]  Jun Wang,et al.  Small-Molecule Inhibition of TNF-α , 2005, Science.

[18]  Michael Karin,et al.  Reactive Oxygen Species Promote TNFα-Induced Death and Sustained JNK Activation by Inhibiting MAP Kinase Phosphatases , 2005, Cell.

[19]  R. Silverstein.  Review: D-Galactosamine lethality model: scope and limitations , 2004 .

[20]  R. Karlsson,et al.  SPR for molecular interaction analysis: a review of emerging application areas , 2004, Journal of molecular recognition : JMR.

[21]  A. Ashkenazi,et al.  Tumor Necrosis Factor An Apoptosis JuNKie? , 2004, Cell.

[22]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[23]  A. Berezov,et al.  Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics* , 2002, The Journal of Biological Chemistry.

[24]  Rebecca L Rich,et al.  Kinetic analysis of estrogen receptor/ligand interactions , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Thurmond,et al.  Kinetics of small molecule inhibitor binding to p38 kinase. , 2001, European journal of biochemistry.

[26]  D. Underwood,et al.  Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Murali,et al.  Modifying TNFalpha for therapeutic use: a perspective on the TNF receptor system. , 2001, Mini reviews in medicinal chemistry.

[28]  J. Naismith,et al.  TNFα and the TNF receptor superfamily: Structure‐function relationship(s) , 2000, Microscopy research and technique.

[29]  K. Kumagai,et al.  Enhancement by galactosamine of lipopolysaccharide(LPS)‐induced tumour necrosis factor production and lethality: its suppression by LPS pretreatment , 1999, British journal of pharmacology.

[30]  R. Murali,et al.  Structure–based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor , 1997, Nature Biotechnology.

[31]  D. Banner,et al.  Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.

[32]  S. Sprang,et al.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. , 1990, The Journal of biological chemistry.

[33]  B. Aggarwal,et al.  Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon , 1985, Nature.

[34]  A. Scherbel,et al.  [NEW CONCEPTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS]. , 1963, Prensa medica argentina.

[35]  Jessica M. Davis,et al.  Small-molecule inhibitors of the interaction between TNF and TNFR. , 2013, Future medicinal chemistry.

[36]  I. Simsek.  TNF inhibitors - new and old agents for rheumatoid arthritis. , 2010, Bulletin of the NYU hospital for joint diseases.

[37]  Santosh A. Khedkar,et al.  Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. , 2010, Current topics in medicinal chemistry.

[38]  R. Silverstein.  D-galactosamine lethality model: scope and limitations. , 2004, Journal of endotoxin research.

[39]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[40]  M. Feldmann,et al.  Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. , 2003, Nature medicine.

[41]  H Kubinyi,et al.  Chance favors the prepared mind--from serendipity to rational drug design. , 1999, Journal of receptor and signal transduction research.

[42]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.